The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
Heart failure (HF) is one of the leading causes of hospital readmissions and health care expenditures. With a vast degree of advancements in the clinical approach and diagnosis, its management protocol is limited in terms of enhancing quality of life and prognosis. Type 2 diabetes mellitus (T2DM...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2018-11-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/the-role-of-sglt-2-inhibition-in-heart-failure |
| Summary: | Heart failure (HF) is one of the leading causes of hospital
readmissions and health care expenditures. With a vast degree
of advancements in the clinical approach and diagnosis,
its management protocol is limited in terms of enhancing
quality of life and prognosis. Type 2 diabetes mellitus (T2DM)
is considered as one of the commonly associated comorbid
conditions in the HF population. The understanding of
the molecular and metabolic models of HF has led to the
utilization of therapeutic goals of T2DM in improving HFrelated
complications. In the recent era, SGLT-2 inhibitors
have shown success in decreasing cardiovascular mortality
in the T2DM population. This article will help the reviewer to
comprehend the pathophysiology of HF and the potential role
of SGLT-2 inhibitors in the management algorithm of HF and its
associated risk factors in T2DM. |
|---|---|
| ISSN: | 1740-4398 1740-4398 |